Ligand Pharmaceuticals, Inc [LGND] stock prices are down -2.03% to $147.01 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The LGND shares have gain 8.58% over the last week, with a monthly amount glided 20.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ligand Pharmaceuticals, Inc [NASDAQ: LGND] stock has seen the most recent analyst activity on April 10, 2025, when Stifel initiated its Buy rating and assigned the stock a price target of $143. Previously, Oppenheimer started tracking the stock with Outperform rating on October 03, 2024, and set its price target to $135. On July 30, 2024, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $130 on the stock. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $310 on February 04, 2021. Barclays started tracking with a Overweight rating for this stock on October 06, 2020, and assigned it a price target of $156. In a note dated March 24, 2020, Argus downgraded an Hold rating on this stock.
The stock price of Ligand Pharmaceuticals, Inc [LGND] has been fluctuating between $93.58 and $151.55 over the past year. Currently, Wall Street analysts expect the stock to reach $155 within the next 12 months. Ligand Pharmaceuticals, Inc [NASDAQ: LGND] shares were valued at $147.01 at the most recent close of the market. An investor can expect a potential return of 5.44% based on the average LGND price forecast.
Analyzing the LGND fundamentals
The Ligand Pharmaceuticals, Inc [NASDAQ:LGND] reported sales of 187.58M for trailing twelve months, representing a surge of 14.68%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.09 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 140.04 points at the first support level, and at 133.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 151.07, and for the 2nd resistance point, it is at 155.14.
Ratios To Look Out For
It’s worth pointing out that Ligand Pharmaceuticals, Inc [NASDAQ:LGND]’s Current Ratio is 5.45. In addition, the Quick Ratio stands at 5.21 and the Cash Ratio stands at 3.79. Considering the valuation of this stock, the price to sales ratio is 15.36, the price to book ratio is 3.44.
Transactions by insiders
Recent insider trading involved KOZARICH JOHN W, Director, that happened on Aug 01 ’25 when 467.0 shares were sold. Director, KOZARICH JOHN W completed a deal on Aug 01 ’25 to buy 467.0 shares. Meanwhile, Director KOZARICH JOHN W sold 934.0 shares on Jul 10 ’25.
